Important Updates on the ViroStat Integration Into Medix Biochemica
In 2023, Medix Biochemica acquired ViroStat to better serve the infectious disease market’s raw material needs with best in class antibody & antigen products.
As part of our integration process, we will be making some changes to order processes and branding that will apply to all ViroStat portfolio products.
In case your company has a Supply or Distributor Agreement in place with Virostat Inc., and you wish to officially amend it to accommodate the changes, please contact your Medix Biochemica representative or reach out to us at medix@medixbiochemica.com.
It is important to note that there will be no changes to:
- The form, fit, or function of any products
- The manufacturing entity, location, processes, or team members that build and ensure the quality of our products
What will be changing?
As from October 1, 2024 the following changes will come into effect:
Minor change in ViroStat product catalogue numbers
As part of ViroStat’s migration to Medix Biochemica’s ERP system, we will be making a minor change to the catalogue numbers of the ViroStat product range.
Change in order process for ViroStat products
US, Europe and Rest of World customers (excluding China, Taiwan and Hong Kong), all orders for ViroStat products must be placed to Medix Biochemica USA Inc, orders@medixbiochemica.com.
For China, Taiwan and Hong Kong customers, all orders for ViroStat products must be placed to Medix Biochemica China, cn.orders@medixbiochemica.com.
You may need to implement a new vendor registration process as part of this change. Our team will be available to support you with this and our company financial details are available to download through the links below.
Change in format of Product Specifications & COA documents for ViroStat products
We will be aligning the format of the product specification and certificate of analysis documents to current Medix Biochemica templates.
Change in logo and branding for ViroStat products
As part of our global brand harmonization project, all product sales documents (sales confirmations, packing slips and invoices), all product quality assurance documents (certificates of analysis, data and specifications sheets) and all product labelling that was previously branded as ViroStat, will be branded as Medix Biochemica.
This change applies to all ViroStat products, Certificates of Analysis, product specifications, and product labelling.
What is in scope of the change?
Document Parameter | Current ViroStat Document | New Medix Biochemica Document |
Catalogue / Item Number Bulk item (≥1mg/mL concentration) |
Item No: 1234 | Item No: V1234 |
Catalogue / Item Number Sample / research item (100µg/mL concentration) |
Item No: 1234 | Item No: V1234S |
Product Description Product type |
MonoTope / OmniTope / MabyRab product descriptions |
Not included / used on new documents |
Product Description Antibody abbreviation |
Aby | Anti |
Logo |
|
|
Our primary objective remains the continuity of product quality, service, and delivery that you have relied on for years.
Should you have any questions, please contact your Medix Biochemica sales representative or call a member of our Customer Service:
USA 1-314-968-1091
Finland +358 9 547680
China +86 21 6811 9180, 6811 9181, 6811 9105
Alternatively, we can be reached by email at: medix@medixbiochemica.com or medixchina@medixbiochemixca.com (for China)